Health agencies update.
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017292:Doxazosin / Q000009:adverse effects*; D015316:Genetic Therapy; D015277:Hotlines; D006801:Humans; D020407:Internet; D009316:National Institutes of Health (U.S.); D011956:Receptors, Cell Surface; D019966:Substance-Related Disorders / Q000628:therapy*; D013649:Taste / Q000502:physiology*; D014481:United States; D014486:United States Food and Drug Administration; D014612:Vaccines
D000317:Adrenergic alpha-Antagonists; D000959:Antihypertensive Agents; D011956:Receptors, Cell Surface; D014612:Vaccines; D017292:Doxazosin